Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocotrienol and Bevacizumab in Metastatic Colorectal Cancer
NCT04245865Phase 2Active, not recruiting
- Sponsor
- Vejle Hospital
- Start
- Jun 2020
- Primary completion
- Mar 2025
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in colorectal cancer (CRC) (2 arms), sponsored by Vejle Hospital. Primary endpoint: Progression-Free Survival Rate at 6 months. Started Jun 2020; status: active, not recruiting.
02
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT04245865.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04245865.